富国银行分析师团队启动了对生物制药公司First Tracks Biotherapeutics Inc.的研究覆盖，并给予其股票“超配”评级。该行同时设定了30美元的目标股价，预示着分析师认为该公司股票在当前水平上具有显著的上行潜力。
富国银行分析师团队启动了对生物制药公司First Tracks Biotherapeutics Inc.的研究覆盖，并给予其股票“超配”评级。该行同时设定了30美元的目标股价，预示着分析师认为该公司股票在当前水平上具有显著的上行潜力。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.